To OTC Journal Members:
 

The Planet Blasts Off

I had a BLOG entry up early Thursday morning for those who might have been looking for guidance on the Commerce Planet (OTC BB: CPNE) story. What a huge win this has proven to be for those who either picked it up this year or averaged their cost down from last year's tough sledding. The stock traded to a low of $.19 in 2006 on March 21st. A mere four months later, the stock closes at $.885- net return of 365% if you had the courage to buy it at the low. 

CPNE is a classic example of how a little faith and luck can be rewarded in the microcap arena. The outstanding corporate performance helps. If the company stays on track there will be little holding this stock back from returning to its previous highs in the $2 range. Will it go straight to $2? - no. There will be bumps and grinds along the way, and your faith will be tested. Can they get derailed? Of course. The business could change. However, if they can simply deliver the same corporate performance in Q3, earnings should come in at about $.06 to $.07 per share, suggesting $.24 to $.28 EPS annually- a $2 stock anytime.

If you're wondering how or when to get on board, here's a chart with my preferred .382% and .618% retracement levels drawn in. Personally, I don't like buying streaking stocks as the get extended. Sooner or later they always pull back. If it were my money, here's where I would be willing to put some capital to work. I would start by taking a partial position on a pullback at the .382% level - $.76. I would complete my position if I was lucky enough to see the stock pullback to the .618 level- in this case $.66. 

Please use the BLOG. I'm going to start posting a new BLOG nearly everyday. To use the BLOG, simply go to the home page at www.otcjournal.com - the BLOG will scroll down automatically on the right side of your screen. The most current journal entries appear in the middle of your screen. Check back frequently for updates particularly when stocks are moving to overbought or oversold levels in volatile markets.
 

Medistem (OTC BB: MDSM) Back in the News- Progressing With More Therapies

I promised everyone an update on Medistem, the Nike of the stem cell industry. Unlike their brethren technology companies, MDSM is embarking on an ambitious plan to actually begin treating patients with adult, non controversial Stem Cells. They plan to do so by licensing their technology to clinics worldwide who can legally treat patients with Stem Cells right now. I call them the Nike of the stem cell industry because, instead of talking about it and researching for the next 10 years, they plan to JUST DO IT!

I don't mean to sound cavalier about such a serious subject. They have done a lot or research, and are ready to treat patients. The first licensed clinic will begin treating patients in San Juan, Costa Rica any day now. They plan to expand world wide in short order once the first clinic is operational.

I like this idea because I believe they will generate a lot of publicity once treatments begin, especially if they happen to deliver some extraordinary results. I can visualize a 60 Minutes segment, or something of the like. 

While we wait for treatments to start, the company is working on some new therapies for a variety of maladies. Friday they filed for a patent in a huge market segment - erectile dysfunction. The estimate - 30 million American men suffer from some form of erectile dysfunction. 

My SSL on this one was $.55 for the summer sell off. Friday, the stock closed at $.36. It's time to have another look if you heeded my advice and got out at higher levels. As you can see from the chart, the stock is well positioned for a rebound. You can see the volume capitulation in late May and early June. This sets us up for easy money for the few who will wade in when no one wants the stock.

Here's Friday's press release for your review:
 

Subscribe

Information is power and timely information is profitable. Become informed and profit from OTC Journal Profiles and Trading Alerts by becoming a Preferred Member today. There is no cost associated with your email subscription. Add your email address below and make sure to check your email inbox and confirm your opt-in request to start receiving the OTC Journal Email Newsletter on a regular basis.

To ensure newsletter delivery, you can add any additional email addresses you may have to the OTC Journal Member List. Receiving the OTC Journal Newsletter in multiple locations is the best way of making sure you don't miss the next investing or trading opportunity! For web based email addresses, the OTC Journal recommends @yahoo.com or @aol.com for timely and reliable email newsletter delivery.

Note: Your email address will be kept strictly confidential, and will not be shared with any other entity for any purpose at any time. If you no longer wish to receive the OTC Journal, simply follow the instructions located at the bottom of every OTC Journal Newsletter Edition.

Go Here to view our compensation on every company we have ever covered, or visit the following web address:  http://www.otcjournal.com/disclaimer.html for our full profiles and http://www.otcjournal.com/trading-alerts/disclaimer.html for Trading Alerts. MarketBtye LLC has been paid of fee of $25,000 in cash and 750,000 newly issued, restricted shares by Commerce Planet  for coverage of the company. All 750,00 have become eligible to be free trading as a result of a registration statement.  For its services in connection with this report and other internet marketing services, MarketByte LLC has been paid a fee of $30,000, and has received warrants to purchase 500,000 shares of the common stock of Medistem Laboratories, Inc. for $0.25 per share, which warrants expire in 2008.  Medistem Laboratories, Inc. is obligated to register the resale of the shares underlying the warrants under the Securities Ac of 1933 . These warrants were transferred by Trilogy Capital Partners, Inc., which received the warrants from Medistem Laboratories, Inc. as part of the compensation for the investor relations services to be provided by Trilogy Capital Partners, Inc.

All statements and expressions are the sole opinions of the editors and are subject to change without notice. A profile, description, or other mention of a company in the newsletter is neither an offer nor solicitation to buy or sell any securities  mentioned. While we believe all sources of information to be factual and reliable, in no way do we represent or guarantee the accuracy thereof, nor the statements made herein.

From time to time MarketByte LLC sells shares in the open market it receives as compensation for coverage of client companies. Since the shares are received as compensation for services as previously disclosed, and not for investment purposes, the editors do not view the sale of the shares as contradictory to any advice delivered in the content. This should be viewed as a conflict of interest by shareholders or prospective shareholders of the client companies.

The editor, members of the editor's family, and/or entities with which they are affiliated aside from MarketBtye LLC itself, are forbidden by company policy to own, buy, sell or otherwise trade stock for their own benefit in the companies who appear in the publication unless specifically disclosed in the newsletter. Some of the companies featured in the OTC Journal pay a cash ESP fee to an affiliated technology company ranging from $2,000 to $5,000 per month for internet related technology services.

The Trustee of the MarketByte LLC Defined Benefit and Trust (“the MarketByte Pension Plan”) has invested approximately $140,0000 in Dutchess Private Equities II LP (“the Dutchess Limited Partnership”), a limited partnership in which the MarketByte Pension Plan is a limited partner. The Trustee of the MarketByte LLC Defined Benefit and Trust (“the MarketByte Pension Plan”) has invested approximately $190,0000 in the Longview Fund (“the Longview Limited Partnership”), both limited partnerships in which the MarketByte Pension Plan is a limited partner. No one associated with the MarketByte Pension Plan has any knowledge, information, or control as to any past, present, or future investment activities of the Dutchess Limited Partnership or the Longview Fund.  The Dutchess Limited Partnership is one of two hedge funds managed by Dutchess Advisors.  Dutchess Advisors and Longview periodically refers companies to MarketByte LLC for possible coverage by one of the MarketByte LLC publications, which publications include The OTCJournal.com Newsletter.  Dutchess Advisors or Longview may or may not own shares in the companies that it so refers to MarketByte. MarketByte has no information (outside of information readily accessible to the general public such as SEC filings) as to whether Dutchess Advisors or Longview owns any shares in the companies that it refers to MarketByte LLC.  The above relationships should be viewed as a potential and/or actual conflict of interest by shareholders and prospective shareholders of MarketByte LLC client companies. 

The profiles, critiques, and other editorial content of the OTCjournal.com may contain statements that appear foward relating to the expected capabilities of the companies mentioned herein.

THE READER SHOULD VERIFY ALL CLAIMS AND DO THEIR OWN DUE DILIGENCE BEFORE INVESTING IN ANY SECURITIES MENTIONED. INVESTING IN  SECURITIES IS SPECULATIVE AND CARRIES A HIGH DEGREE OF RISK. THE INFORMATION FOUND IN THIS PROFILE IS PROTECTED BY THE COPYRIGHT LAWS OF THE UNITED STATES AND MAY NOT BE COPIED, OR REPRODUCED IN ANY WAY WITHOUT THE EXPRESSED, WRITTEN  CONSENT OF THE EDITORS OF OTCjournal.com.

We encourage our readers to invest carefully and read the investor information available at the web sites of  the Securities and Exchange Commission ("SEC") at http://www.sec.govand/or the National Association of Securities Dealers ("NASD") at http://www.nasd.com. We also strongly recommend that you read the SEC advisory to investors concerning Internet Stock Fraud, which can be found at  http://www.sec.gov/consumer/cyberfr.htm. Disclaimer ID:$subst('Recip.userid') Readers can review all public filings by companies at the SEC's EDGAR page. The NASD has published information on how to invest carefully at its web site.  MarketByte LLC's mailing address is 4653 Carmel Mtn Rd Suite 308 #402, San Diego, CA 92130.